PharmaCyte Biotech (PMCB) Stock Price, Financials & Analysis

Key Stats

Market Cap3.76 Mn

P/E-0.18

Div. Yield0.00

Add ratio to table…

About

PharmaCyte Biotech, Inc. is a biotechnology company focused on developing cellular therapies for cancer using its proprietary cellulose based live cell encapsulation technology. The company’s lead product candidate CypCaps™ is intended for the treatment of locally advanced inoperable non metastatic pancreatic cancer. PharmaCyte Biotech, Inc. is incorporated in Nevada and maintains its headquarters in Las Vegas Nevada. PharmaCyte Biotech, Inc. has not yet generated…

How PharmaCyte Biotech ranks

Ranked against the 668 companies in Pharmaceuticals and Biotechnology58 metrics · as of Oct 21, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.18xMedian 16.8x 7^th
P/FCFNegative free cash flow −0.93xMedian 18.3x 19^th
P/Operating cash flowNegative operating cash flow −0.93xMedian 17.0x 18^th
P/S —Median 9.38x No data —
P/B 0.13xMedian 2.17x 96^th
P/Tangible book 0.13xMedian 2.42x 96^th
EV/EBITDA —Median 15.7x No data —
EV/EBITNet cash exceeds market value 2.02xMedian 19.8x Not meaningful —
EV/Revenue —Median 6.59x No data —
EV/FCFNet cash exceeds market value 3.60xMedian 19.2x Not meaningful —
EV/Operating cash flowNet cash exceeds market value 3.60xMedian 16.0x Not meaningful —
PEG (3Y EPS CAGR)Negative earnings 0.00Median 0.33 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) —Median 10.2% No data —
Revenue CAGR (3Y) —Median 10.2% No data —
Gross profit growth (1Y) —Median 10.6% No data —
Gross profit CAGR (3Y) —Median 10.7% No data —
Operating income growth (1Y) −77.2%Median 0.0% 16^th
Operating income CAGR (3Y) −0.8%Median 1.6% 46^th
Net income growth (1Y) −1,335%Median −5.1% 2^nd
Net income CAGR (3Y) −39.4%Median −0.4% 14^th
EPS growth (1Y) −134%Median 21.0% 12^th
EPS CAGR (3Y) −36.4%Median 25.3% 11^th
Operating cash flow growth (1Y) 14.3%Median 0.3% 64^th
Operating cash flow CAGR (3Y) −18.5%Median 2.4% 25^th
Free cash flow growth (1Y) 14.3%Median 0.3% 64^th
Free cash flow CAGR (3Y) −18.5%Median 3.3% 24^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin —Median 74.0% No data —
EBITDA margin —Median −216% No data —
Operating margin —Median −230% No data —
Pretax margin —Median −223% No data —
Net margin —Median −230% No data —
FCF margin —Median −168% No data —
Operating cash flow margin —Median −157% No data —
Return on equity −20.8%Median −53.5% 75^th
Return on assets −15.2%Median −42.0% 76^th
Return on invested capital —Median −5.3% No data —
Return on capital employed −17.1%Median −46.0% 77^th
Asset turnover —Median 0.18x No data —
Cash conversion (OCF / net income)Net income is not positive 0.24xMedian 1.21x Not meaningful —
Stock comp / revenue —Median 27.5% No data —

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets —Median 20.0% No data —
Debt / equity —Median 0.26x No data —
Net debt / EBITDA —Median 1.82x No data —
Debt / FCF —Median 3.03x No data —
Liabilities / assets 25.1%Median 32.8% 60^th
Equity / assets 74.9%Median 67.2% 60^th
Interest coverage —Median −10.1x No data —
Current ratio 40.3xMedian 4.48x 98^th
Quick ratio 23.2xMedian 3.72x 95^th
Cash ratio 23.2xMedian 3.34x 95^th
Altman Z-score —Median −0.62 No data —

Peer group

Peer Comparison

Companies in the Gene and Cell Therapy

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,175.59 Bn	44.01	14.76	54.91 Bn
2	JNJ	Johnson & Johnson	639.41 Bn	30.39	6.53	49.04 Bn
3	ABBV	AbbVie Inc.	502.56 Bn	79.64	7.81	70.82 Bn
4	MRK	Merck & Co., Inc.	375.27 Bn	118.27	5.64	53.91 Bn
5	NVS	Novartis Ag	303.16 Bn	19.22	5.54	9.59 Bn
6	AZN	Astrazeneca Plc	268.63 Bn	25.72	4.58	32.35 Bn
7	AMGN	Amgen Inc	242.12 Bn	27.69	6.36	57.30 Bn
8	PMCB	PharmaCyte Biotech, Inc.	0.00 Bn	-0.18	-	-

PharmaCyte Biotech PMCB

About

How PharmaCyte Biotech ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

PharmaCyte Biotech PMCB

About

How PharmaCyte Biotech ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password